CompletedPhase 3NCT03473613

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Benha University
Principal Investigator
Ashraf N Elmantwe, MD
Benha University
Intervention
Oral Cabergoline(drug)
Enrollment
230 target
Eligibility
18-45 years · FEMALE
Timeline
20142017

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03473613 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

See all trials for Ovarian hyperstimulation syndrome

← Back to all trials